Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough
In response to an audience member who asked him if he would have done anything differently in regard to raising the price of the drug, Daraprim, Shkreli replied, “I probably would have raised the price higher.”
That price hike, which brought a pill of Daraprim from $13.50 to $750 earlier this year, has drawn fiery scorn from the public, media, and lawmakers. Daraprim is a 62-year old drug used to treat toxoplasmosis, a disease caused by a parasitic infection. Toxoplasmosis often strikes people with compromised immune systems, such as AIDS patients.
During the 25-minute interview, Shkreli explained the price hike regret. “I could have raised it higher and made more profits for our shareholders, which is my primary duty,” he said.
Source: Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica